{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bipolar-disorder/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"61d98476-085c-58c4-b646-093d1564a66c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2537c354-2e50-47eb-9dd1-344204862989 --><h2>Changes</h2><!-- end field 2537c354-2e50-47eb-9dd1-344204862989 -->","summary":null,"htmlStringContent":"<!-- begin item 430cb7d5-3555-45db-9210-b09b1ffe1fd7 --><!-- begin field 23f6b688-e724-4cd8-b172-caad806ebd8e --><p><strong>February 2021 </strong>— minor update. Photosensitivity added as an adverse effect of lamotrigine in line with updated manufacturer's SPC.</p><p><strong>November 2020 </strong>— minor update. New recommendation to monitor blood concentration of some antipsychotics has been added to the Antipsychotics Monitoring section.</p><p><strong>March 2020 </strong>— minor update. Salivary hypersecretion has been added to the adverse effects of antipsychotic medications in line with manufacturer's SPC.<br><br><strong>February 2020</strong> — minor update. The recommendation that women or young girls of childbearing potential who are already taking valproate should be advised to gradually stop the medicine because of the risk of fetal malformations and adverse neurodevelopmental outcomes after any exposure in pregnancy was added to this topic in line with the updated NICE guideline <em>Bipolar disorder: assessment and management</em>.  </p><p><strong>June 2019</strong> — reviewed and updated. A literature search was conducted in June 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 23f6b688-e724-4cd8-b172-caad806ebd8e --><!-- end item 430cb7d5-3555-45db-9210-b09b1ffe1fd7 -->","topic":{"id":"ac644ce3-3932-5e1f-8676-4ebcfb5f240d","topicId":"87d084eb-bc7f-45b7-9384-f490e6417d9d","topicName":"Bipolar disorder","slug":"bipolar-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"3ed6a7a1-589c-57a9-89fd-e61f76a4c198","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96f8d073-2e2b-55bd-9f94-a0cf336756a7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5a048129-7c1e-5fc5-8a8a-3e91b2be7e18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d98476-085c-58c4-b646-093d1564a66c","slug":"changes","fullItemName":"Changes"},{"id":"e8e86070-9a3a-5b97-8a3b-d76771dd7e92","slug":"update","fullItemName":"Update"}]},{"id":"308f8462-ca53-5dee-9a6a-463a88283762","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e56ddcf1-8ade-5c55-ada8-cd9307fa9d45","slug":"goals","fullItemName":"Goals"},{"id":"c9a278dc-a960-595c-90fa-702a979fe434","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6c858f7e-b8a9-5125-9b30-d15ff9489c89","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"caccf5a3-718b-556f-a3d7-e412c84fffec","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1d1a32a6-8f9b-54ef-8db8-35685fd71f28","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"31f4b1ea-76e5-5273-821f-7ba3fd77ac0e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b529213a-3211-53f9-b870-f03b9a1d30c9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"53fd9729-258a-5bc1-ac8d-c7c2ebdfd92e","slug":"definition","fullItemName":"Definition"},{"id":"0dc41761-cd41-54cc-8277-c96320874497","slug":"causes","fullItemName":"Causes"},{"id":"2c7c3452-f7d6-5a4d-ac13-72ecad737a44","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"7a53a39d-073b-5a29-b48d-a0ff3049049e","slug":"complications","fullItemName":"Complications"},{"id":"ae1afd6c-efdb-5d1f-82a9-ee9a07103bde","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"45d991bb-5121-511b-a201-826c8297a59d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff54cf2c-7ebb-58b5-a77c-a285db95f263","slug":"suspecting-bipolar-disorder","fullItemName":"Suspecting bipolar disorder"},{"id":"a5cf6d30-ba09-58fa-b2a2-78490ef3dfe6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0c45d8c8-9038-5e75-9637-34b9b70a708f","fullItemName":"Management","slug":"management","subChapters":[{"id":"08d1a671-233b-56fe-9343-455ae9d9457c","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"3168933b-1d1b-56e0-82d5-13b7a4175ed1","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"7fd5675a-5f41-5662-86a1-dcd7103d1e7b","slug":"routine-bipolar-disorder-review","fullItemName":"Scenario: Routine bipolar disorder review"},{"id":"7cd1d695-071f-5e74-945f-e61927a44a85","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"7be9863d-b620-5545-b0ca-d2a5ea14af95","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d0da96ab-51ae-530a-ac52-76b445fb10a5","slug":"ssris","fullItemName":"SSRIs"},{"id":"7ccedc62-ec67-54d4-a721-f520c7573553","slug":"antipsychotics","fullItemName":"Antipsychotics"},{"id":"587e9545-d869-5933-b101-2407ad59bc52","slug":"lamotrigine","fullItemName":"Lamotrigine"},{"id":"f1925178-1888-5bf8-8868-92a526afff0f","slug":"lithium","fullItemName":"Lithium"},{"id":"1933741e-2f27-57bf-92f1-5d769518344f","slug":"valproate","fullItemName":"Valproate"}]},{"id":"1913037b-d494-5a34-be7c-baf4cb96acd4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"88a92260-20b8-51eb-8b46-3a2409ddf63b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"438d8ad5-e57e-58be-8902-0a3160dc221d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4449bc7-d64d-5a1c-a07a-b9a548cc3172","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"be352ccd-5a94-556d-b076-f450b54edbfb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"999ad09a-2f9f-562d-9583-938295801e7f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a2be53e8-c67a-5bbd-a684-a352c46d9902","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c4e156df-5e61-50f0-bcf6-60433f5a4e37","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5a048129-7c1e-5fc5-8a8a-3e91b2be7e18","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"898c4bf1-7f18-5d73-af28-c5ae8be2aa5c","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 7788a25d-9fdc-4d13-bfdf-1f1e200d702d --><h3>Previous changes</h3><!-- end field 7788a25d-9fdc-4d13-bfdf-1f1e200d702d -->","summary":null,"htmlStringContent":"<!-- begin item acca231b-2963-4720-83e5-93efadd85ece --><!-- begin field 203ae27e-d3fd-4479-92a0-d2e2410c6105 --><p><strong>September 2017</strong> — minor update. Nimodipine added to the interactions section for valproate.</p><p><strong>December 2016</strong> — minor update.</p><ul><li>Drug Reaction associated with Eosinophilia and Systemic Symptoms (DRESS) has been added as an adverse effect of olanzapine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2016a</a>]. </li><li>Drug Reaction associated with Eosinophilia and Systemic Symptoms (DRESS) has been added as an adverse effect of lamotrigine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2016b</a>].</li><li>A Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update <em>Valproate and risk of abnormal pregnancy outcomes: new communication materials</em> recommendation to use new support tools to support discussion about the risks of valporate in pregnancy has been added to this topic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">MHRA, 2016</a>].</li></ul><p><strong>October 2016</strong> — minor update. Information added on reported cases of misuse and abuse with quetiapine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2016c</a>].</p><p><strong>October 2015 </strong>— minor update. Muscle weakness and rhabdomyolysis have been included as possible adverse effects of lithium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI Medicines Compendium, 2015a</a>].</p><p><strong>May 2015 </strong>— minor update. Three updates based on updates to manufacturers' Summaries of Product Characteristics (SPCs):</p><ul><li>Mitochondrial disorders added as a contraindication to the use of valproate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI Medicines Compendium, 2015b</a>].</li><li>Renal tumours (microcysts, oncocytomas, and collecting duct renal carcinoma) added as possible adverse effects of prolonged use (over 10 years) of lithium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI Medicines Compendium, 2015a</a>].</li><li>Nightmares added as an adverse effect of lamotrigine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI Medicines Compendium, 2015c</a>].</li></ul><p><strong>March 2015 </strong>— minor update. Update to the text to incorporate the recommendation from the MHRA that valproate should not be prescribed to female children, female adolescents, women of childbearing potential or pregnant women unless other treatments are ineffective or not tolerated.</p><p><strong>February 2015 </strong>— minor update. Diplopia added as an uncommon side effect with aripiprazole based on an update to the SPC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI Medicines Compendium, 2014</a>].</p><p><strong>July 2014 to November 2014 </strong>— reviewed. A literature search was conducted in May 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Changes have been made in line with the NICE guideline <em>Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">NICE, 2014</a>].</p><p><strong>July 2013</strong> — minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013</strong> — minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>March 2012</strong> — minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012</strong> — minor update. New information about the rare association of quetiapine with diabetic ketoacidosis has been added. Issued in February 2012.</p><p><strong>January 2012</strong> — minor update. Relevant information from the Medicines and Healthcare products Regulatory Agency (MHRA) about a risk of extra-pyramidal effects or withdrawal symptoms (or both) in newborns after maternal use of anti-psychotics during the third trimester of pregnancy has been added to this topic. Issued in January 2012.</p><p><strong>May 2011</strong> — minor update. Relevant recommendations from the NICE guideline <em>Psychosis with coexisting substance misuse </em>have been incorporated into this topic. The 2011/2012 QOF indicators have also been added to this topic. Issued in June 2011.</p><p><strong>May 2011</strong> — interaction between SSRIs and tamoxifen added as stated in the most recent SPCs. Issued in June 2011.</p><p><strong>February 2011</strong> — topic structure revised to ensure consistency across CKS topics - no changes to clinical recommendations have been made.</p><p><strong>October 2010</strong> — minor update. Information on fitness to drive from the Driver and Vehicle Licensing Agency's guidance for medical practitioners, <em>At a glance guide to the current medical standards of fitness to drive </em>has been added. Issued in October 2010.</p><p><strong>July 2010</strong> — minor update. Prescribing information on Lithium updated to reflect new advice in the Summary of Product Characteristics (SPC) that one 5 mL spoonful of Priadel<sup>®</sup>liquid (520 mg lithium citrate) is equivalent to 204 mg lithium carbonate, not 200 mg lithium carbonate as stated on previous SPCs. Issued in July 2010.</p><p><strong>May 2010</strong> — minor update. Minor amendment to lithium prescribing issues (minor typographical error). Issued in June 2010.</p><p><strong>January 2010</strong> — minor update regarding interactions between lithium and antidepressants. Issued in January 2010.</p><p><strong>December 2009</strong> — minor update. The National Patient Safety Agency has developed a lithium patient information leaflet, a lithium alert card, and a record book for tracking blood tests. Issued in December 2009.</p><p><strong>October 2009</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded prescribers that smoking induces metabolism of olanzapine and clozapine, so stopping smoking can increase levels of these drugs, possibly causing increased adverse effects. Issued in October 2009.</p><p><strong>April 2009</strong> — minor update. The Quality and Outcomes Framework (QOF) indicators for stopping smoking related to bipolar disorder have been added to the <em>QOF indicators </em>section. Issued in May 2009.</p><p><strong>September 2008 to February 2009</strong> — this is a new CKS topic developed following a structured literature review. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 203ae27e-d3fd-4479-92a0-d2e2410c6105 --><!-- end item acca231b-2963-4720-83e5-93efadd85ece -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}